Glaxo's Imitrex injectable sumatriptan
Executive Summary
Will be reviewed for use in the treatment of migraine by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on Oct. 25. Glaxo filed the NDA (#20-080) for injectable sumatriptan on June 29, 1990 and filed for approval of a slower-acting oral form on Dec. 14, 1990. On Oct. 24, the advisory committee meeting will be closed to discuss trade secret and/or confidential information on pending INDs. Glaxo's drug will be reviewed in an open meeting scheduled for 8 a.m.-5 p.m. The committee will meet at FDA's Parklawn Bldg., Conference Rooms D&E. . . .
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: